A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Dose-Finding Study of MK-0822 in the Treatment of Involutional Osteoporosis
Latest Information Update: 09 May 2022
At a glance
- Drugs Odanacatib (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 17 Apr 2020 Results (n=1280) of pooled analysis from phase 1 (P005, P025, and P014), phase 2b (P004 and P022), and phase 3 (P018) , assessing population pharmacokinetic (PK) model in postmenopausal women for odanacatib, published in the Journal of Clinical Pharmacology
- 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
- 24 Mar 2012 Results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.